Jose Baselga

发表

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Alejandra Bruna, J. Mora, J. Baselga, 2007, Cancer cell.

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

Pablo Tamayo, Ian F. Dunn, Shuji Ogino, 2008, Nature.

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Carsten Denkert, Stefan Michiels, Christos Sotiriou, 2015, JAMA oncology.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Jordi Rodon, Irene Braña, J. Baselga, 2013, Clinical Cancer Research.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Richard Bell, Mitch Dowsett, 2017, The Lancet.

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

John M. S. Bartlett, Stefan Michiels, Christos Sotiriou, 2013, PloS one.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Manuel Hidalgo, Xin Huang, Shujian Wu, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESR1 ligand binding domain mutations in hormone-resistant breast cancer

David Chen, Sarat Chandarlapaty, Zhiqiang Li, 2013, Nature Genetics.

Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers.

Funda Meric-Bernstam, Jason Roszik, Vivek Subbiah, 2020, Cancer discovery.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Gordon B Mills, Neal Rosen, Francesco Hofmann, 2006, Cancer research.

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Sridhar Ramaswamy, Mehmet Toner, Min Yu, 2013, Science.

Oncologic therapy shapes the fitness landscape of clonal hematopoiesis

Ahmet Zehir, Stuart Gardos, Nilanjan Chatterjee, 2019, bioRxiv.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

David M. Hyman, Vivek Subbiah, Jordi Rodon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

Catherine Wheeler, J. Baselga, G. Sledge, 2005, Clinical Cancer Research.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization

Carlos L. Arteaga, J. Baselga, F. Rojo, 2002, Nature Medicine.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Guy Jerusalem, Cristina Saura, J. Baselga, 2014, Clinical Cancer Research.

Epidermal growth factor receptor targeting in cancer.

John Mendelsohn, J. Baselga, J. Mendelsohn, 2006, Seminars in oncology.

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

Carlos L Arteaga, J. Baselga, C. Arteaga, 2004, Cancer cell.

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Sarat Chandarlapaty, Violeta Serra, Maurizio Scaltriti, 2011, Cancer cell.

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Ronglai Shen, Jorge S. Reis-Filho, Nikolaus Schultz, 2018, Cancer cell.

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Ahmet Zehir, Kenneth Offit, Barry S Taylor, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation.

J. Baselga, Jose Baselga, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

Donavan T. Cheng, Marc Ladanyi, David M Hyman, 2015, Drug discovery today.

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

Marion Procter, Thomas Suter, R. Gelber, 2017, The New England journal of medicine.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Ulrik B Nielsen, U. Nielsen, J. Baselga, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

Roy S Herbst, W. Hong, J. Baselga, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

Robert Langer, Michael J. Cima, John T. Santini, 2015, Science Translational Medicine.

Targeting Tyrosine Kinases in Cancer: The Second Wave

J. Baselga, Jose Baselga, 2006, Science.

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Susan Quinn, Gunnar Folprecht, Josep Tabernero, 2008, Clinical Cancer Research.

The EGF receptor family as targets for cancer therapy

John Mendelsohn, J. Baselga, J. Mendelsohn, 2000, Oncogene.

TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

David García-Dorado, Juan Sahuquillo, Ignasi Barba, 2009, Cancer cell.

AACR Cancer Progress Report 2013

Elaine R Mardis, Peter J Neumann, Ahmedin Jemal, 2013, Clinical Cancer Research.

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion

Kristian Cibulskis, Gad Getz, Shuji Ogino, 2011, Nature Genetics.

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

John W. Cassidy, James Hadfield, Carlos Caldas, 2016, Cell.